The countdown to a make-or-break clinical readout at Sellas Life Sciences has taken on an extra layer of intrigue. With 78 of the 80 required deaths now recorded in the Phase 3 REGAL trial of Galinpepimut‑S (GPS) for acute myeloid leukemia – as of 11 May 2026 – the biotech player stands just two events away from triggering a full survival analysis. Yet the stock’s recent surge, which lifted it to a fresh 52‑week high of €13.00, owes its momentum to more than just trial progress. Investors have seized on a strengthening balance sheet and a set of management compensation changes that, in the deal‑driven world of biotech, are often read as curtain‑raisers for a potential sale.
Sellas has redrawn the severance packages for its top executives, including the CEO and CFO. Under the revised terms, a change‑of‑control triggers lump‑sum payouts and immediate vesting of stock options. Such “golden parachute” provisions are common in the sector when boards anticipate a buyer knocking at the door. That possibility, combined with the approaching REGAL endpoint, has drawn heavy buying pressure. Over the past week alone, the stock rocketed roughly 70 %, following a 12‑month run that now stands at nearly 590 %.
Cash runway widens
The company’s financial position provides ample runway for whatever comes next. Pro forma cash and equivalents stood at US $135.8 million as of early June 2026, bolstered by US $28.7 million raised through warrant exercises in April and May. At the end of the first quarter, the war chest had already reached US $107.1 million, a steep climb from the US $71.8 million recorded at the close of 2025. That liquidity not only covers the ongoing REGAL trial but also funds a second promising programme: a randomised Phase 2 study of SLS009 (Tambiciclib), a selective CDK9 inhibitor being tested in newly diagnosed AML patients unlikely to benefit from standard azacitidine‑venetoclax therapy. Around 80 patients will be enrolled using predictive biomarkers and AI‑driven precision medicine, with initial results expected in the fourth quarter of 2026.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
Technical warning lights flash
The blistering rally has pushed the shares well beyond conventional technical boundaries. At €12.70, the stock trades at roughly twice its 50‑day moving average of €6.33. The 14‑day relative strength index sits at 84.9 – deep in overbought territory – while the annualised volatility clocks in at 123 %. For traders, those readings suggest the advance may be overheating, but the underlying catalysts keep the speculative bid intact.
In the near term, all eyes remain on the REGAL death‑event count. Once the 80th occurrence is confirmed, the clock starts ticking on the final data readout. A positive outcome could rewrite the company’s valuation; a negative one would leave the market questioning the path forward. Until then, the combination of bulging cash, C‑suite protections, and a trial on the cusp of resolution makes Sellas Life Sciences one of the most closely watched names in small‑cap biotech.
Ad
Sellas Life Sciences Stock: Buy or Sell?! New Sellas Life Sciences Analysis from June 29 delivers the answer:
The latest Sellas Life Sciences figures speak for themselves: Urgent action needed for Sellas Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 29.
Sellas Life Sciences: Buy or sell? Read more here...
